Association Between Body Mass Index and Colorectal Neoplasia at Follow-Up Colonoscopy: A Pooling Study

Jacobs, Elizabeth T.; Ahnen, Dennis J.; Ashbeck, Erin L.; Baron, John A.; Greenberg, E. Robert; Lance, Peter; Lieberman, David A.; McKeown‐Eyssen, Gail; Schatzkin, Arthur; Thompson, Patricia A.; Martı́nez, Marı́a Elena

doi:10.1093/aje/kwn401

Cited by 80 publications

(68 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have evaluated the association of body size with adenoma recurrence [17 – 19]. Jacobs et al [18] reported an increased odds of adenoma recurrence with overweight (OR = 1.13; 95% CI: 1.01 – 1.26) and obesity (OR = 1.29; 95% CI: 1.14 – 1.45) over a median follow-up of 47.2 months among 8,213 patients. These positive associations were only found in men.…”

Section: Discussionmentioning

confidence: 99%

“…We performed stratified analyses by sex for both BMI and weight change since previous studies have reported differences by sex in the association between obesity and adenoma recurrence [17, 18]. We also investigated the effect of weight change on any adenoma recurrence by baseline BMI categories.…”

Section: Methodsmentioning

confidence: 99%

“…Three studies have examined the association between BMI and the risk of adenoma recurrence [17 – 19]. These studies suggested an increased risk of adenoma recurrence in association with high body mass index but two of the studies reported a differential association by sex with the increased risk only for men [17 – 18]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Obesity, weight change, and risk of adenoma recurrence: a prospective trial

et al. 2012

View full text Add to dashboard Cite

Background and study aims Obesity is a risk factor for colorectal neoplasia. Lifestyle modifications including weight loss have been advocated to reduce the risk. However, no prospective study has evaluated if weight loss actually affects adenoma recurrence. We examined whether weight change (loss or gain) over four years is associated with adenoma recurrence. Patients and methods 1,826 participants with colorectal adenoma in the Polyp Prevention Trial had height and weight measured at baseline. Adenoma recurrence was determined by end of trial colonoscopy 4 years after study entry when participants’ weights were re-measured. We used Poisson regression models to evaluate body mass index (BMI), weight change over 4 years and the risk of any adenoma and advanced adenoma recurrence. Results 723 (39.6%) participants had adenoma recurrence, of whom 118 (6.5%) had advanced adenoma recurrence. Among those with baseline BMI < 25 kg/m2 (n=466), BMI = 25–29 kg/m2 (n=868), and BMI ≥ 30 kg/m2 (n=492), the recurrence rate was 34.5%, 41% and 41.9%, respectively. Obesity was associated with an increased risk of adenoma (RR=1.19; 95%CI: 1.01–1.39) and advanced adenoma recurrence (RR=1.62; 95%CI: 1.01–2.57). However, when compared with those with relatively stable weight (< 5 pound weight change) over the 4-year trial, weight gain or loss was not associated with adenoma recurrence. This was consistent, regardless of the baseline BMI. Conclusions Weight loss or gain over 4 years does not affect adenoma recurrence. Our study does not support weight loss alone as an effective intervention for reducing adenoma recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Obesity, weight change, and risk of adenoma recurrence: a prospective trial

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Some data also indicate a potential link between obesity and polyamine inhibition in humans (46); besides, an association between obesity and risk of CRA has been reported (47). In spite of these observations, in a recent study it has been shown that obesity does not substantially modify the CRA risk reduction ascribed to DFMO plus sulindac versus placebo (48).…”

Section: Influence Of Drugs On Polyamine Metabolism For Crc Chemoprevmentioning

confidence: 99%

Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (Review)

Linsalata¹,

Orlando²,

Russo³

2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Chemoprevention is the long-term use of different chemical agents, both synthetic and natural, to prevent or delay the onset of disease. Since colorectal cancer has a significant environmental component, it is an ideal disease in which to evaluate the potential benefits of chemopreventive agents. The polyamines, spermine, spermidine and putrescine have been involved in almost all the steps of colorectal tumorigenesis. Consequently, polyamine biosynthesis and catabolism can be considered as promising targets for cancer chemoprevention. A variety of drug formulations have been tested for their efficacy in affecting polyamines in a strategy of colorectal cancer prevention. Different molecules, such as biosynthesis inhibitors and catabolism inducers, have been proposed alone or in combination with other drugs proved to diminish the colorectal cancer risk. Interestingly, also diet can play a role in cancer prevention by affecting polyamines. Several dietary components, such as probiotics or flavonoids, have been shown to affect the polyamine metabolic pathway in colorectal neoplastic tissue. On the other hand, the polyamines ingested with diet might contrast the above cited effects shown by both drugs and nutritional factors. It is, therefore, fundamental to acquire more data also on these aspects in view of an innovative approach to colorectal oncology. This review summarizes data on the role of polyamine metabolism in neoplastic transformation of colorectal mucosa and as possible target for colorectal cancer chemoprevention. Attention will be focused on the influence of drugs and nutritional factors on polyamine metabolism, as well as the role played by dietary polyamines.

show abstract

“…CIMP carcinomas tend to be located in the proximal colon and show more mucinous and poorly differentiated histology [16]. Tumors evolving through the serrated tumor pathway exhibit different risk factors; patient at risk groups respond differently to chemotherapy and vary in prognosis compared to traditional adenomas, although findings of concerned studies are not concordant [17,18,19,20,21,22,23,24,25,26,27]. Notably, sporadic serrated tumors are strongly associated with BRAF V600E mutations [28].…”

Section: Introductionmentioning

confidence: 99%

Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer

et al. 2015

View full text Add to dashboard Cite

Aims: To investigate tumor and patient characteristics of individuals with mismatch repair (MMR)-deficient colorectal carcinomas. Methods: We immunhistochemically investigated tissue samples of 307 consecutive patients with colorectal cancer for defects in DNA MMR proteins (hMLH1, hMSH2, hMSH6, hPMS2) and those with mutations further for microsatellite instability (MSI) and BRAF V600E mutations. Results: 32/308 (10.4%) tumors showed MMR deficiency. Seventy five percent (n = 24) had loss of hMLH1 and hPMS2 expression, 3% (n = 1) of hPMS2 alone, 18.8% (n = 6) of hMSH6 and hMSH2, 3% (n = 1) of hMSH2 alone. All MMR-deficient tumors showed high MSI. These tumors occurred preferably in the right-sided colon, in women and showed specific histological features. We obtained the family history of 18/32 patients; 2 (11.1%) met Amsterdam Criteria, 5 (27.8%) Bethesda Guidelines and 6 (33.3%) revised Bethesda Guidelines. BRAF V600E mutations were found in 16 (67%) of hMLH1 and none of the hMSH2 deficient tumors. Conclusion: We suggest using immunhistochemical testing of tumor tissues with subsequent MSI analysis, which may be justified as a screening method for MMR deficiency in colorectal cancer, since it identifies patients with possibly hereditary defects and unalike response to chemotherapy.

show abstract

Association Between Body Mass Index and Colorectal Neoplasia at Follow-Up Colonoscopy: A Pooling Study

Cited by 80 publications

References 53 publications

Obesity, weight change, and risk of adenoma recurrence: a prospective trial

Obesity, weight change, and risk of adenoma recurrence: a prospective trial

Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (Review)

Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer

Contact Info

Product

Resources

About